# US 2024/0003907 A1 · Methods of assessing risk of and treating preeclampsia and subtypes thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0003907 A1
- Document ID: US20240003907A1
- Status: Published application
- Kind: A1
- Application number: 18/096,464
- Filed: 2023-01-12
- Published: 2024-01-04
- Earliest claimed: 2020-07-13
- Assignees: Nx Prenatal Inc.; The Brigham and Women's Hospital, Inc.
- Applicants: NX Prenatal Inc.; The Brigham and Women's Hospital, Inc.
- Inventors: Kevin P. ROSENBLATT; Thomas F. MCELRATH
- Web page: https://patentgrep.com/patent/US20240003907A1

## CPC

- G01N 33/689: {related to pregnancy or the gonads}
- A61P 5/00: Drugs for disorders of the endocrine system
- G01N 33/5076: {involving cell organelles, e.g. Golgi complex, endoplasmic reticulum}
- G01N 33/6848: {Methods of protein analysis involving mass spectrometry}
- G01N 33/86: involving blood coagulating time {or factors, or their receptors}
- G01N 2333/4716: Complement proteins, e.g. anaphylatoxin, C3a, C5a
- G01N 2333/4737: C-reactive protein
- G01N 2333/745: Assays involving non-enzymic blood coagulation factors
- G01N 2333/75: Fibrin; Fibrinogen
- G01N 2333/78: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
- G01N 2333/96458: Factor XII (3.4.21.38)
- G01N 2800/368: Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
- G01N 2800/50: Determining the risk of developing a disease
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein are CMP-associated proteins, collected between 10-12 weeks of gestation, that can be used to stratify the risk of later preeclampsia requiring delivery at <=35 weeks of gestation. For those that screen positive, clustering can be used to further characterize the putative subtype of the preeclampsia. Risk stratification and disease phenotype characterizations such as this can optimize prophylactic and therapeutic interventions.

## Claims

### Claim 1

A method for determining a subtype of preeclampsia in a pregnant subject, the method comprising:
(a) preparing a microparticle-enriched fraction from a blood sample from a pregnant subject at increased risk of preeclampsia;
(b) determining a measure of a panel of microparticle-associated protein biomarkers in the fraction, wherein the panel includes at least one coagulation-related biomarker and/or at least one complement activity-related biomarker; and
(c) assessing the form of preeclampsia based on the measure, wherein:
altered expression of a coagulation-related biomarker indicates blood coagulation-associated preeclampsia; and altered expression of a complement activity-related biomarker indicates complement-type preeclampsia.

### Claim 2 (depends on 1)

The method of claim 1, further comprising determining that the subject is at increased risk of preeclampsia:
(a) determining a measure of one or more microparticle-associated protein biomarkers in a microparticle-enriched fraction from the subject, wherein the one or more protein biomarkers are associated with increased risk of preeclampsia; and
(c) determining an increased risk of the risk of preeclampsia, based on the measure or measures.

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The method of claim 1, wherein the panel comprises (1) complement C1r subcomponent protein (C1RL), platelet glycoprotein 1b alpha chain (GP1BA), vitronectin (VTNC), and zinc-alpha-2-glycoprotein (ZA2G) or (2) complement C1r subcomponent protein (C1RL), platelet glycoprotein 1b alpha chain (GP1BA), vitronectin (VTNC), and beta-2-glycoprotein 1 (APOH).

### Claim 5 (depends on 1, 2)

The method of claim 1, 2, or 3, wherein:
(i) the at least one coagulation-related biomarker is selected from the group consisting of Immunoglobulin J chain, Zinc finger protein 251, Extracellular matrix protein 1, CD5 antigen-like, and Alpha-2-macroglobulin; and
(b) the at least one complement activity-related biomarkers is selected from the group consisting of Vitronectin, Pigment epithelium-derived factor, Complement C4-A, Prothrombin, Highly similar to Complement factor B, Complement C3, Angiotensinogen, Complement C2, Phosphatidylinositol-glycan-specific phospholipase D, Coagulation factor XII, Complement factor H, Calcium-dependent secretion activator 1, C-reactive protein, Kininogen-1, Heparin cofactor 2, Hemopexin, and Bone marrow proteoglycan.

### Claim 6 (depends on 1)

The method of claim 1, wherein the altered expression associated with coagulation-associated preeclampsia is an increased expression compared with normal, and/or the altered expression associated with complement activity-associated preeclampsia is an increased expression compared with normal.

### Claim 7

A method of treating a subtype of preeclampsia in a pregnant subject comprising:
(a) determining whether the subject is at increased risk of coagulation-associated preeclampsia or complement activity-type preeclampsia, wherein determining comprises associating a measure of one or more protein coagulation-related biomarkers or one or more complement activity-related biomarkers with coagulation-associated preeclampsia or complement activity-type preeclampsia; and
(b) treating the subject as follows:
(1) if the subject is determined to be at increased risk of coagulation-associated preeclampsia, administering to the subject a therapeutic intervention to decrease abnormal blood coagulation; or
(2) if the subject is determined to be at increased risk of complement activity-type preeclampsia, administering to the subject a therapeutic intervention to decrease abnormal complement activity.

### Claim 8 (depends on 7)

The method of claim 7, comprising, before determining the type of preeclampsia, determining that the subject is at increased risk for preeclampsia.

### Claim 9 (depends on 7)

The method of claim 7, wherein the therapeutic intervention for coagulation-associated preeclampsia, comprises administration of a platelet aggregation inhibitor, optionally wherein the platelet aggregation inhibitor is selected from the group consisting of aspirin, clopidogrel, cilostazol, prasugrel, ticagrelor, caplacizyumab.

### Claim 10 (depends on 7)

The method of claim 7, wherein the therapeutic intervention for complement activity-type type preeclampsia, comprises administration of a pharmaceutical selected from the group consisting of a protease inhibitor, a soluble complement regulator, an anti-complement antibody, a complement component inhibitor, and a receptor antagonist.

### Claim 11

A method for assessing risk of preeclampsia requiring delivery in <=35 weeks gestation, in a pregnant subject, the method comprising:
(a) preparing a microparticle-enriched fraction from a blood sample from the pregnant subject;
(b) determining a measure of one or more a panel of microparticle-associated protein biomarkers in the fraction, wherein the panel comprises one or more protein biomarkers arc selected from:
(i) a protein biomarker of Table 2; and
(ii) a protein biomarker of Table 3; and
(c) assessing the risk of preeclampsia requiring delivery at <=35 weeks gestation based on the measure.

### Claim 12 (depends on 11)

The method of claim 11, wherein assessing the risk comprises distinguishing risk of preeclampsia requiring delivery at <=35 weeks gestation and preeclampsia not requiring delivery at <=35 weeks gestation.

### Claim 13 (depends on 11)

The method of claim 11, wherein an increased amount of an up-regulated biomarker or a decreased amount of a down-regulated biomarker indicates increased risk of preeclampsia requiring delivery in <=35 weeks gestation.

### Claim at position 14

-15. (canceled)

### Claim 16 (depends on 11)

The method of claim 11, wherein the panel comprises a plurality of biomarkers selected from GP1BA, VTNC, C1RL, ZA2G, APOC2, APOH, and JPH1.

### Claim 17 (depends on 11)

The method of claim 11, wherein the panel comprises complement C1r subcomponent protein (C1RL), platelet glycoprotein 1b alpha chain (GP1BA), vitronectin (VTNC), and zinc-alpha-2-glycoprotein (ZA2G).

### Claim 18 (depends on 11)

The method of claim 11, wherein the panel comprises complement C1r subcomponent protein (C1RL), platelet glycoprotein 1b alpha chain (GP1BA), vitronectin (VTNC), and beta-2-glycoprotein 1 (APOH).

### Claim 19

The method of claim, wherein the panel comprises no more than any of 10, 9, 8, 7, 6, 5, or 4 protein biomarkers.

### Claim 20 (depends on 11)

The method of claim 11, wherein the sample is taken from the pregnant subject during the first trimester or second trimester of pregnancy.

### Claim 21 (depends on 20)

The method of claim 20, wherein the sample is taken from the pregnant subject during weeks 10-12 of gestation.

### Claim 22 (depends on 11)

The method of claim 11, wherein the pregnant subject is primigravida, multigravida, primiparous or multiparous.

### Claim 23 (depends on 11)

The method of claim 11, wherein the pregnant subject has a singleton pregnancy or multiple pregnancy.

### Claim 24 (depends on 11)

The method of claim 11, wherein the pregnant subject:
(a) is asymptomatic for preeclampsia;
(b) has no history of preeclampsia;
(c) has no other risk factors for preeclampsia; or
(d) has chronic hypertension.

### Claim at position 24

-27. (canceled)

### Claim 28 (depends on 11)

The method of claim 11, wherein the blood sample is plasma or serum.

### Claim 29 (depends on 11)

The method of claim 11, wherein the microparticle-enriched fraction is prepared using size-exclusion chromatography.

### Claim at position 27

-33. (canceled)

### Claim 34 (depends on 11)

The method of claim 11, wherein the microparticles are further purified to enrich for placental-derived exosomes or vascular endothelial-derived exosomes.

### Claim 35 (depends on 11)

The method of claim 11, wherein determining a measure comprises:
(a) mass spectrometry;
(b) liquid chromatography/mass spectrometry (LC/MS);
(c) liquid chromatography/triple quadrupole mass spectrometry; or
(d) multiple reaction monitoring.

### Claim at position 30

-40. (canceled)

### Claim 41 (depends on 35)

The method of claim 35, wherein determining the measure comprises determining a measure of a surrogate peptide of the protein biomarker.

### Claim at position 32

-46. (canceled)

### Claim 47 (depends on 11)

The method of claim 11, wherein the assessing comprises executing a classification rule, which rule classifies the subject as being at increased risk of preeclampsia requiring delivery in <=±weeks gestation, as being at increased risk of blood coagulation-associated preeclampsia and/or as being at increased risk of complement-type preeclampsia, and wherein execution of the classification rule produces a correlation between preeclampsia requiring delivery in <=±weeks gestation or term birth with a p value of less than at least 0.05.

### Claim 48 (depends on 1)

The method of claim 1, wherein the assessing comprises executing a classification rule, which rule classifies the subject at being at risk of preeclampsia, and wherein execution of the classification rule produces a receiver operating characteristic (ROC) curve, wherein the ROC curve has an area under the curve (AUC) of at least 0.6, at least 0.7, at least 0.8 or at least 0.9.

### Claim 49 (depends on 1)

The method of claim 1, wherein values on which the classification rule classifies a subject further include at least one of: maternal age, maternal body mass index, primiparous, and smoking during pregnancy.

### Claim 50 (depends on 11)

The method of claim 11, wherein the classification rule employs cut-off, linear regression (e.g., multiple linear regression (MLR), partial least squares (PLS) regression, principal components regression (PCR)), binary decision trees (e.g., recursive partitioning processes such as CART - classification and regression trees), artificial neural networks such as back propagation networks, discriminant analyses (e.g., Bayesian classifier or Fischer analysis), logistic classifiers, and support vector classifiers (e.g., support vector machines).

### Claim at position 37

-66. (canceled)

### Claim 67

A computer-implemented method for generating a model to assess a risk of preeclampsia, the computer-implemented method comprising:
obtaining a dataset, the dataset comprising measurements associated with a plurality of biomarkers derived from each of a plurality of subjects; and
implementing a machine learning analysis to associate a set of biomarkers within the plurality of biomarkers with preeclampsia, wherein implementing the machine learning analysis generates a model to assess the risk of preeclampsia, wherein the risk of preeclampsia is one or more of risk of preeclampsia requiring delivery in <=±weeks gestation, risk of blood coagulation-associated preeclampsia and risk of complement-activity related preeclampsia, wherein the set of biomarkers are selected from the biomarkers of Table 2, Table 3, and Table 4.

### Claim at position 39

-71. (canceled)

### Claim 72

A computer-implemented method of assessing a risk of preeclampsia in a subject, the computer-implemented method comprising:
determining a quantitative measure of at least one biomarker in a sample; and
executing a classification rule based on the quantitative measure,
wherein the execution of the classification rule assesses the risk of preeclampsia in the subject (e.g. risk of preeclampsia requiring delivery in <=±weeks gestation, risk of blood coagulation-associated preeclampsia and/or risk of complement-activity related preeclampsia), and
wherein the classification rule implements at least one of cut-offs, linear regression, binary decision trees, artificial neural networks, discriminant analyses, logistic classifiers, and support vector classifiers,
wherein the at least one biomarker is selected from the biomarkers of Table 2, Table 3, and Table 4.

### Claim at position 41

-75. (canceled)
